We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cardinal (CAH) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
Read MoreHide Full Article
The upcoming report from Cardinal Health (CAH - Free Report) is expected to reveal quarterly earnings of $2.15 per share, indicating an increase of 3.4% compared to the year-ago period. Analysts forecast revenues of $55.03 billion, representing an increase of 0.2% year over year.
The consensus EPS estimate for the quarter has been revised 0.1% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
That said, let's delve into the average estimates of some Cardinal metrics that Wall Street analysts commonly model and monitor.
The consensus among analysts is that 'Revenue- Pharmaceutical and Specialty Solutions' will reach $50.33 billion. The estimate points to a change of -0.6% from the year-ago quarter.
It is projected by analysts that the 'Revenue- Medical Products and Distribution' will reach $3.21 billion. The estimate indicates a year-over-year change of +3.2%.
Analysts forecast 'Segment profit- Pharmaceutical and Specialty Solutions' to reach $635.77 million. Compared to the present estimate, the company reported $580 million in the same quarter last year.
Analysts predict that the 'Segment profit- Global Medical Products and Distribution' will reach $44.16 million. The estimate is in contrast to the year-ago figure of $20 million.
Over the past month, Cardinal shares have recorded returns of +0.8% versus the Zacks S&P 500 composite's -4.3% change. Based on its Zacks Rank #3 (Hold), CAH will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Cardinal (CAH) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
The upcoming report from Cardinal Health (CAH - Free Report) is expected to reveal quarterly earnings of $2.15 per share, indicating an increase of 3.4% compared to the year-ago period. Analysts forecast revenues of $55.03 billion, representing an increase of 0.2% year over year.
The consensus EPS estimate for the quarter has been revised 0.1% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
That said, let's delve into the average estimates of some Cardinal metrics that Wall Street analysts commonly model and monitor.
The consensus among analysts is that 'Revenue- Pharmaceutical and Specialty Solutions' will reach $50.33 billion. The estimate points to a change of -0.6% from the year-ago quarter.
It is projected by analysts that the 'Revenue- Medical Products and Distribution' will reach $3.21 billion. The estimate indicates a year-over-year change of +3.2%.
Analysts forecast 'Segment profit- Pharmaceutical and Specialty Solutions' to reach $635.77 million. Compared to the present estimate, the company reported $580 million in the same quarter last year.
Analysts predict that the 'Segment profit- Global Medical Products and Distribution' will reach $44.16 million. The estimate is in contrast to the year-ago figure of $20 million.
View all Key Company Metrics for Cardinal here>>>
Over the past month, Cardinal shares have recorded returns of +0.8% versus the Zacks S&P 500 composite's -4.3% change. Based on its Zacks Rank #3 (Hold), CAH will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>